About Us

 

Triflo Cardiovascular, Inc. is a Southern California – based corporation founded in 2017. In a span of less than 6 years including the Covid pandemic crisis, our talented team of engineers and advisors have developed the company’s patented technologies from inception to clinical use.

 
 

Luca Pesce – Co-Founder – Chief Executive Officer

•          15+ years of experience focused on leading teams to engineering and clinically validate transcatheter heart valve technologies (TAVI, TMVR, TTVR)

•          In 2012 led the development of CardiAQ Valve Technology’s Transcatheter Mitral Valve Replacement (TMVR) to the successful clinical testing of the worldwide first self-expanding TMVR valve implantable via trans-apical and trans-septal clinical procedures. Results brought CardiAQ’s acquisition years ahead of plan by Edwards LifeSciences, a market leader in heat valve prostheses

•          Previously held lead R&D engineering positions at Edwards Lifesciences focused on pioneering R&D of early-stage TAVI delivery systems.

 
 

Prof. Dr. Gian Paolo Ussia, FACC FSCAI – Co-Founder – Chief Scientific Officer

•          Full Professor of Cardiology Campus Bio-Medico University of Rome, Italy

•          Pioneer in transcatheter valvular heart interventions:

•          First-in-Human (FIH) MDT CoreValve implanter in Italy (June 4th, 2007)

•          FIH implanter Abbott Mitraclip in Italy (7th October 2008)

•          Worldwide FIH implanter of Edwards-CardiAQ trans-septal mitral valve prosthesis (June 2015)

 
 
 
 

Stephane Piat – Co-founder – Chairman of the Board

•          Senior Executive with 20+ years experience in senior management roles among Becton Dickson, J&J and Abbott

•          Currently CEO of CARMAT

•          Previously Division Vice President (Global Market Development) for Abbott Vascular

 

Frank Ahmann – Chief Business Officer

•          Senior executive with 30 years of experience in the biotech and medical device industries.

•           Successfully developed cardiovascular technologies and executed clinical trials from proof of concept to Phase IV for devices and biologics in Australia, China, Eastern and Western Europe, and North and South America.

•          Following leadership positions at Baxter Biotech Group and Cardiovascular Group, built five startup ventures and raised more than $75 million. In 2022, sold Heart Failure startup MateraCor, Inc. to Bioventrix, Inc.